EICHORPublic-registry site landscape for NCT05268289, “Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V”, a Lupus Nephritis study sponsored by Novartis Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05268289 (registry record) |
| Study title | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V |
| Official title | An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids in Patients With Active Lupus Nephritis Class III-IV, +/- V |
| Sponsor | Novartis Pharmaceuticals |
| Condition(s) | Lupus Nephritis |
| Phase | PHASE2 |
| Listed sites | 103 |
| Site countries | United States, Argentina, Brazil, China, Colombia, France, Germany, Hong Kong, Hungary, India, Israel, Malaysia |
Patient-friendly overview of this study: eichor.com/study/NCT05268289.
Eichor generates a preliminary site-risk snapshot for NCT05268289 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
More from Novartis Pharmaceuticals
← Eichor home · All tracked trials · Lupus Nephritis studies · Weekly briefs
